Transdiagnostic treatment in a face-to-face setting for emotional disorders in Arabic- and Farsi-speaking refugees: a randomized controlled study

Transdiagnostic treatment in a face-to-face setting for emotional disorders in Arabic- and Farsi-speaking refugees: a randomized controlled study - ALMAMAR

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

DRKS

Registry ID

DRKS00033041

Enrollment

130

Registered

2023-12-19

Start date

2023-12-10

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F39 F41.1 F41.0 F40.0 F40.1 F43 F10 F19 F63

Interventions

Group 1: Face-to-face Intervention: 6-16 weeks of face-to-face treatment using the Common Elements Treatment Approach. Individualized allocation of therapy modules based on diagnostic information. Con

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: -Full legal age -Primary diagnosis of a depressive disorder, post-traumatic stress disorder (PTSD), or an anxiety disorder (generalized anxiety disorder, panic disorder, agoraphobia, social anxiety disorder) according to DSM-5 -Arabic and/or Farsi language proficiency (spoken and written) -Access to the Internet (smartphone or computer) -Consent to the informed consent agreement

Exclusion criteria

Exclusion criteria: -Current psychotic or bipolar disorder -Severe substance use disorder (AUDIT Score >15 for men, >13 for women; DUDIT Score >25) -Acute suicidality (lack of or unclear distancing; no capacity for agreement) -Suicide attempt in the last 12 months -Ongoing psychotherapy or unstable medication with psychotropic drugs three months prior the start of the study

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the change in psychological distress, assessed using the total score of the HSCL-25 self-report version (from pre- to post-treatment).	—

Secondary

Measure	Time frame
As secondary outcomes, depression will be assessed using the HSCL-25-Depression subscale, anxiety using the HSCL-25-Anxiety subscale, and post-traumatic symptoms using the PCL-5. Suicidality will be assessed through suicide screening during the diagnostic interviews over the phone. To evaluate alcohol consumption, the AUDIT will be employed and for drug consumption, the DUDIT will be used. The EQ-5D-5L will be utilized to measure quality of life and simultaneous somatic symptom burden. Treatment satisfaction will be assessed with the CSQ-I. Potential side effects will be recorded using the NEQ.	—

Measure

Time frame

As secondary outcomes, depression will be assessed using the HSCL-25-Depression subscale, anxiety using the HSCL-25-Anxiety subscale, and post-traumatic symptoms using the PCL-5. Suicidality will be assessed through suicide screening during the diagnostic interviews over the phone. To evaluate alcohol consumption, the AUDIT will be employed and for drug consumption, the DUDIT will be used. The EQ-5D-5L will be utilized to measure quality of life and simultaneous somatic symptom burden. Treatment satisfaction will be assessed with the CSQ-I. Potential side effects will be recorded using the NEQ.

—

Countries

Germany

Contacts

Public ContactMartina Hernek

Freie Universität Berlin

ALMAMAR@ewi-psy.fu-berlin.de+493083862672

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 14, 2026